Constantiam Biosciences
Constantiam Biosciences is a preclinical functional genomics company that uses Deep Mutational Scanning combined with Bayesian generative modeling to resolve variants of uncertain significance, serving pharmaceutical, diagnostics, and clinical genetics laboratory customers across four integrated platforms.
- Company typePrivate
- Founded2020
- HeadquartersWatertown, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Constantiam Biosciences does
Constantiam Biosciences is a preclinical-stage functional genomics company founded in 2020 and headquartered in Watertown, Massachusetts, with additional offices in Seattle, Boston, and Houston. The company builds and operates four integrated platforms — RareScan, MAVEvidence, Genable, and StratiVar — that combine Deep Mutational Scanning (DMS) assays with Bayesian generative modeling and probabilistic machine learning to classify genetic variants of uncertain significance (VUS), generate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for clinical trials. Its primary customers are pharmaceutical companies, diagnostics firms, and clinical genetics laboratories that need scalable functional evidence to support variant interpretation, drug discovery, and trial enrollment; the company also maintains a discovery-stage internal therapeutic pipeline led by CB-001 in lysosomal storage disorders, anchored by a June 2026 strategic collaboration with Cincinnati Children's Hospital Medical Center for neuronopathic Gaucher disease (Types 2 and 3).
The underlying technology is the integration of massively multiplexed cellular assays with human biobank data, enabling classification of thousands of variants simultaneously rather than one at a time. MAVEvidence reportedly contains 476,000+ pieces of evidence across 327,500+ genetic variants, and the company cites peer-validated outcomes including 49% of observed VUS being reclassifiable and 69% of BRCA1 VUS reclassified through MAVE data integration. The platform suite is positioned to support ACMG/AMP variant classification frameworks, regulatory submissions, and clinical trial design.
Constantiam's revenue model rests on three pillars: (1) non-dilutive U.S. federal SBIR grants, including a $2.05M Phase II award from NHGRI and a $485K Phase I award from the National Institute on Aging, totaling approximately $2.535M to date; (2) B2B platform services and data licensing to pharma and diagnostics clients, supported by data licensing deals such as the September 2025 OHSU agreement; and (3) an emerging therapeutic pipeline with potential licensing economics, currently supported by a seed fundraising round. The company employs 1–10 people, generates no publicly disclosed commercial revenue, distributes through direct enterprise sales and content marketing, and is led by co-founders Nicholas Schafer (CEO), Daniel Goldman (CSO), and Norman Ong (CCO) alongside a scientific advisory bench drawn from the Broad Institute, Stanford, and the University of Pittsburgh.
Constantiam Biosciences firmographics
Firmographics- Name
- Constantiam Biosciences
- Legal name
- Constantiam Biosciences
- Website
- https://constantiambio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Constantiam Biosciences is a preclinical functional genomics company that uses Deep Mutational Scanning combined with Bayesian generative modeling to resolve variants of uncertain significance, serving pharmaceutical, diagnostics, and clinical genetics laboratory customers across four integrated platforms.
- Ownership category
- akta.pro rank
Constantiam Biosciences industry classification
Industry- Product category
- Functional Genomics Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Constantiam Biosciences is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Constantiam Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D
Revenue model
- Government Grants (SBIR): Small Business Innovation Research (SBIR) grants from U.S. federal agencies including NHGRI ($2.05M Phase II) and NIA ($485,000 Phase I) supporting platform development and early-stage research.
- Platform Services: Functional genomics platform services for pharma and diagnostics companies, including variant analysis, patient stratification, and drug target discovery.
- Seed Funding: Company is raising a seed round to advance pipeline through biomarker-driven development toward IND-enabling studies and First-in-Human trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Silver Pack |
| Subscription | Monthly | Gold Pack |
| Subscription | Monthly | Platinum Pack |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Constantiam Biosciences product offering
Product offeringCore offering
Constantiam Biosciences operates four functional genomics platforms (RareScan, MAVEvidence, Genable, and StratiVar) that integrate massively multiplexed Deep Mutational Scanning experiments with human biobank data and probabilistic machine learning to classify variants of uncertain significance (VUS), curate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for rare disease clinical trials. The company also advances a preclinical therapeutic pipeline (CB-001) targeting lysosomal storage disorders including neuronopathic Gaucher disease Types 2 and 3.
Product overview
Constantiam Biosciences offers a suite of four integrated functional genomics platforms—RareScan, MAVEvidence®, Genable, and StratiVar—that work together to classify genetic variants, support clinical decision-making, and accelerate precision medicine. RareScan uses Deep Mutational Scanning to classify variants of uncertain significance and predict drug responses for rare disease patients. MAVEvidence® serves as the functional evidence database, curating and presenting evidence from high-throughput variant studies for the clinical genetics community. Genable enables drug target discovery and prioritization through massively-multiplexed experiments and machine learning. StratiVar supports patient stratification for clinical trials by assessing therapeutic susceptibility across protein variants. The company also develops CB-01, a discovery-stage therapeutic program for lysosomal storage disorders.
Differentiator
Problem solved
Functional benefit
Brands
- RareScan™: Patient expansion platform using Deep Mutational Scanning (DMS) to classify variants of uncertain significance (VUS) and predict drug responses, improving patient access to treatments and clinical trial stratification for rare diseases.
- MAVEvidence®
- Genable™
- StratiVar™
Products and services
- RareScan
Quantifiable outcome
- 49% of VUS observed by clinical laboratories could be reclassified through MAVE integration
- +2 more outcomes
Companies that use Constantiam Biosciences
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Constantiam Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Constantiam Biosciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- Cincinnati Children's Hospital Medical CentercoreStrategic collaboration through exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3). Combines Cincinnati Children's validated preclinical data with Constantiam's RareScan functional genomics platform to match therapeutic candidates to responsive patient genotypes across hundreds of GBA1 mutations.
- Oregon Health & Science University (OHSU)coreLicense agreement with OHSU to access data from Dr. Brian O'Roak's laboratory, supporting variant interpretation capabilities.
- Variant Interpretation for Cancer Consortium (VICC)supportingDr. Nicholas Schafer presented MAVEvidence platform for clinical variant interpretation to consortium members, discussing data flow, infrastructure, and considerations for data collection and harmonization.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Constantiam Biosciences competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery company that combines high-throughput wet-lab biology with machine learning for target identification and drug development. Highly comparable to Constantiam in marrying functional genomics experimentation with ML to accelerate precision-medicine discovery, though at significantly larger scale.
- Maze Therapeutics: Functional genomics company using variant-function maps and high-throughput biology to discover precision medicines for genetic diseases. Closely comparable to Constantiam in combining functional genomics with rare-disease therapeutic focus and a variant-interpretation angle.
- Insitro: Machine-learning-driven drug discovery company using high-throughput cellular biology and functional genomics data. Directly comparable in applying ML to large-scale biological experiments for target discovery and patient stratification, though at substantially greater scale and capital base.
- Deep Genomics: AI-focused company developing genetic medicines by predicting variant effects and identifying oligonucleotide-based therapies. Comparable to Constantiam in using computational/ML approaches to interpret genetic variation and develop rare-disease therapeutics.
- Variantyx: Clinical genetics diagnostics company focused on rare-disease variant interpretation and whole-genome sequencing. Comparable to Constantiam in emphasizing functional evidence and clinical-grade variant classification for rare-disease diagnostics.
Broad incumbents
- SOPHiA Genetics: Established clinical genomics platform using AI to analyze complex genomic and radiomic data for hospitals and clinical labs. Comparable to Constantiam's MAVEvidence platform in serving clinical genetics labs for variant interpretation, but at much larger scale as a publicly traded incumbent.
- Fabric Genomics (now GeneDx): AI-driven clinical genomics interpretation platform for hereditary disease variant classification, now part of GeneDx. Directly comparable to Constantiam's MAVEvidence platform in supporting clinical variant interpretation workflows for hospitals and labs.
- GeneDx: Major clinical genomics laboratory serving pediatric rare-disease and hereditary disease diagnostics, with significant variant-interpretation capability following the Fabric Genomics acquisition. Comparable as a large potential customer/competitor for Constantiam's MAVEvidence platform.
Emerging players
- CAMP4 Therapeutics: Functional genomics company focused on regulatory non-coding RNAs for rare disease therapeutics. Comparable to Constantiam in leveraging functional genomics data and computational approaches to drive rare-disease drug discovery at similar stage.
Others
- n-Lorem Foundation: Non-profit that develops individualized antisense oligonucleotide therapies for ultra-rare disease patients identified through clinical genetic testing. Comparable as a partner/customer ecosystem for functional genomics platforms like RareScan that classify patient-specific VUS for rare disease.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Constantiam Biosciences social profiles
Digital presenceConstantiam Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Constantiam Biosciences leadership team
Management profileNumber of profiles
Profiles13 records
Constantiam Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Constantiam Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Constantiam Biosciences
What does Constantiam Biosciences do?
Constantiam Biosciences operates four functional genomics platforms (RareScan, MAVEvidence, Genable, and StratiVar) that integrate massively multiplexed Deep Mutational Scanning experiments with human biobank data and probabilistic machine learning to classify variants of uncertain significance (VUS), curate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for rare disease clinical trials. The company also advances a preclinical therapeutic pipeline (CB-001) targeting lysosomal storage disorders including neuronopathic Gaucher disease Types 2 and 3.
Is Constantiam Biosciences a public or private company?
Constantiam Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Constantiam Biosciences founded?
Constantiam Biosciences was founded in 2020. It employs 1 to 10 people.
Where is Constantiam Biosciences based?
Constantiam Biosciences is headquartered in Watertown, United States, in the North America region.
How does Constantiam Biosciences make money?
Three revenue lines are on record. Government Grants (SBIR) is the primary driver. The others are platform Services and seed Funding.
Who are Constantiam Biosciences's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Maze Therapeutics, Insitro, Deep Genomics and Variantyx. Broad incumbents are SOPHiA Genetics, Fabric Genomics (now GeneDx) and GeneDx. CAMP4 Therapeutics is listed as an emerging player. n-Lorem Foundation is listed as an others.
Does Constantiam Biosciences have an API?
No public API is recorded for Constantiam Biosciences.
What industry is Constantiam Biosciences in?
Constantiam Biosciences's product category is Functional Genomics Software. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.